Molecular structure of Sunitinib Malate, CAS Number: 341031-54-7
Sunitinib Malate (CAS 341031-54-7)
See product citations (4)
Alternate Names:
SU-11248
Application:
Sunitinib Malate is an antineoplastic agent, Flk-1 inhibitor, and ATP-competitve inhibitor of PDGFRβ
CAS Number:
341031-54-7
Purity:
≥97%
Molecular Weight:
532.56
Molecular Formula:
C26H33FN4O7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sunitiba Malate is an antineoplastic agent and a potent RTK inhibitor which includes Flk-1 (VEGFR2) as a primary target. It also is a potent, ATP-competitive inhibitor of VEGFR, PDGFR-beta and c-Kit (KIT). Sunitiba Malate inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models. Sunitinib Malate is an inhibitor of c-Fms-CSF-1R, Flt-1, Flt-3/Flk-2, Flt-4, PDGFR-alpha and Ret.
Sunitinib Malate (CAS 341031-54-7) References
- Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. | Sonpavde, G., et al. 2009. Urol Oncol. 27: 391-9. PMID: 18534874
- Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. | Younus, J., et al. 2010. Curr Oncol. 17: 4-10. PMID: 20697509
- Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. | Yoon, CY., et al. 2011. Korean J Urol. 52: 55-63. PMID: 21344032
- Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. | Chan, ES., et al. 2012. Urology. 80: 736.e1-5. PMID: 22676953
- Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro. | Wen, J., et al. 2015. Cancer Cell Int. 15: 26. PMID: 25745360
- Effects of sunitinib malate on growth of human bladder transitional cell line T24 in vitro. | Wen, J., et al. 2015. Chin Med Sci J. 30: 51-5. PMID: 25837361
- Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas. | Ferguson, MJ., et al. 2016. Pediatr Blood Cancer. 63: 206-13. PMID: 26375012
- Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. | Numakura, K., et al. 2018. Oncotarget. 9: 25277-25284. PMID: 29861870
- Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy. | Li, W., et al. 2020. Int Immunopharmacol. 81: 106227. PMID: 32078941
- Sunitinib malate-loaded biodegradable microspheres for the prevention of corneal neovascularization in rats. | Yang, J., et al. 2020. J Control Release. 327: 456-466. PMID: 32822742
- Sunitinib malate inhibits intestinal tumor development in male ApcMin/+ mice by down-regulating inflammation-related factors with suppressing β-cateinin/c-Myc pathway and re-balancing Bcl-6 and Caspase-3. | Chen, L., et al. 2021. Int Immunopharmacol. 90: 107128. PMID: 33191180
- Sunitinib malate inhibits hemangioma cell growth and migration by suppressing focal adhesion kinase signaling. | Scholtz, W. and Mabeta, P. 2020. J Appl Biomed. 18: 143-151. PMID: 34907767
- Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019). | Sheppard-Olivares, S., et al. 2022. Vet Rec Open. 9: e27. PMID: 35079406
- Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach. | Ahmed, MM., et al. 2022. Polymers (Basel). 14: PMID: 35746034
Inhibitor of:
α-protein kinase 3, 1700008P02Rik, AAMP, ACP1, AFP, ALG11, Alix, AML-2, AMPKγ3, Ang-1, APPL1, ARA55, ATAD1, B7-H4, BAALC, BC057079, BPAG1n3, Brx, c-Fms-CSF-1R, c-Kit, C-TAK1, C11orf94, C20orf117, C20orf160, C330005M16Rik, C530044N13Rik, CARD11, ChM-I, CRS4C-4, CTGLF1, DCIR2, DOCK 5, EAT-2B, EGFL7, EVI2B, EYA3, FAM75C2, FHL-5, Flk-1, Flt-1, Flt-3/Flk-2, Flt-4, folliculin, FOXP3, Gm447, Gm609, Gm960, GRASP, GRB14, IFN-αR, ILEI, ISCA2, KRIM-1, LAX1, LERK-3, Ly6G6f, MA3, MAGE-C3, MAP-2D, Mare, MAST1, MFG, Myeloid lineage, neuroligin X/Y, NF2, NOK, NUCKS, Olfr157, Olfr481, Olfr543, Olfr628, Olr110, Olr111, Olr1220, Olr125, Olr1384, Olr144, Olr153, Olr159, Olr160, Olr163, Olr165, Olr168, Olr180, Olr185, Olr232, Olr309, Olr354, Olr367, Olr410, Olr72, Olr80, Olr838, Olr92, OTTMUSG00000005931, OTTMUSG00000010552, OTTMUSG00000010673, OTTMUSG00000016453, Pbx 2, PCDHGC, PDGF-C, PDGFR, PDGFR-alpha, PDGFR-beta, PEAR1, PKD1, PKR1, PRL-3, PTP-MEG2, Ran BP-M, Ret, RETL2, robo4, RREB1, Rse, SEF14, Shc4, Slap, SUP, Tau-2, TCL-1B4, TCP-c, TEL, TGaseZ, Thrombospondin 4, TIM-3, TP53INP1, TRAAK, Trav6d-5, TRBV3, TREM-2b, TREM-2c, TRIQK, TTBK2, Tyrosine Kinase, ZNF211, and ZNF30.Activator of:
Bim, Clusterin, DOCK11, EGFL6, Endoglin, FLTR3, NP1, P23, Ral GDS, SHIP-1, and St. Louis encephalitis.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sunitinib Malate, 10 mg | sc-220177 | 10 mg | $193.00 | |||
Sunitinib Malate, 100 mg | sc-220177A | 100 mg | $510.00 | |||
Sunitinib Malate, 3 g | sc-220177B | 3 g | $1072.00 |